Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference
January 05 2022 - 8:30AM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage
biopharmaceutical company focused on Artificial Intelligence
(“AI”)-driven therapeutic drug development for the treatment of
non-alcoholic steatohepatitis (“NASH”) and other liver diseases,
today announced that the Company’s Chief Medical Officer, Dr. Todd
Hobbs, will present data from the Phase 2 ‘AMBITION’ study at the
NASH-TAG 2022 Conference, which is being held January 6-8, 2022, in
Park City, Utah.
Oral Presentation Details
Title: Investigating CRV431 in NASH Patients:
Data from the Phase 2a AMBITION Study
Session: NOVEL TARGETS
Date: Saturday, January 8, 2022
Time: 10:30 AM MST
Hepion’s AMBITION abstract was one of only nine
“distinguished” abstracts selected for an oral presentation at the
meeting.
“We are very pleased to have been selected to
share the positive AMBITION study data with clinicians,
researchers, and regulators at NASH-TAG, one of the most
prestigious and clinically focused NASH meetings globally,” said
Dr. Hobbs.
A copy of the presentation materials will be
accessible on the Company’s website at www.hepionpharma.com under
“Publications” in the Pipeline section.
About Hepion
Pharmaceuticals
The Company's lead drug candidate, CRV431, is a
potent inhibitor of cyclophilins, which are involved in many
disease processes. CRV431 is currently in clinical-phase
development for the treatment of NASH, with the potential to play
an important role in the overall treatment of liver disease - from
triggering events through to end-stage disease. CRV431 has been
shown to reduce liver fibrosis and hepatocellular carcinoma tumor
burden in experimental models of NASH; and has demonstrated
antiviral activities towards HBV, HCV, and HDV through several
mechanisms, in nonclinical studies.
Hepion has created a proprietary AI platform,
called AI-POWR™, which stands for Artificial
Intelligence - Precision Medicine;
Omics (including genomics, proteomics,
metabolomics, transcriptomics, and lipidomics);
World database access; and
Response and clinical outcomes. Hepion intends to
use AI-POWR™ to help identify which NASH patients will best respond
to CRV431, potentially shortening development timelines and
increasing the delta between placebo and treatment groups. In
addition to using AI-POWR™ to drive its ongoing NASH clinical
development program, Hepion intends to use the platform to identify
additional potential indications for CRV431 to expand the company's
footprint in the cyclophilin inhibition therapeutic space.
For further information, please contact:
Stephen KilmerHepion Pharmaceuticals Investor
RelationsDirect: (646)
274-3580skilmer@hepionpharma.com
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Apr 2023 to Apr 2024